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Abstract: Bronchial asthma is recognized as a highly prevalent health problem in the 
developed and developing world with signiﬁ  cant social and economic consequences. Increased 
asthma severity is not only associated with enhanced recurrent hospitalization and mortality 
but also with higher social costs. The pathogenetic background of allergic-atopic bronchial 
asthma is characterized by airway inﬂ  ammation with inﬁ  ltration of several cells (mast cells, 
basophils, eosinophils, monocytes, and T-helper (Th)2 lymphocytes). However, in atopic 
asthma the trigger factors for acute attacks and chronic worsening of bronchial inﬂ  ammation 
are aeroallergens released by pollens, dermatophagoides, and pets, which are able to induce an 
immune response by interaction with IgE antibodies. Currently anti-inﬂ  ammatory treatments 
are effective for most asthma patients, but there are asthmatic subjects whose disease is not 
completely controlled by inhaled or systemic corticosteroids and who account for a signiﬁ  cant 
portion of the healthcare costs of asthma. A novel therapeutic approach to asthma and other 
allergic respiratory diseases involves interference in the action of IgE, and this antibody has 
been viewed as a target for novel immunological drug development in asthma. Omalizumab is 
a humanized recombinant monoclonal anti-IgE antibody approved for treatment of moderate 
to severe IgE-mediated (allergic) asthma. This non-anaphylactogenic anti-IgE antibody inhibits 
IgE functions, blocking free serum IgE and inhibiting their binding to cellular receptors. By 
reducing serum IgE levels and IgE receptor expression on inﬂ  ammatory cells in the context 
of allergic cascade, omalizumab represents a new class of mast cells stabilizing drugs; it is a 
novel approach to the treatment of atopic asthma. Omalizumab therapy is well tolerated and 
signiﬁ  cantly improves symptoms and disease control, reducing asthma exacerbations and the 
need to use high dosage of inhaled corticosteroids. Moreover, omalizumab improves quality 
of life of patients with severe persistent allergic asthma which is inadequately controlled by 
currently available asthma medications. In conclusion omalizumab may fulﬁ  l an important need 
in patients with moderate to severe asthma.
Keywords: airway hyper-reactivity, asthma, allergic respiratory diseases, atopic respiratory 
diseases, anti-IgE therapy, hypersensitivity, monoclonal anti-IgE antibody, omalizumab
Introduction
Bronchial asthma is a chronic disease of airways which is recognized as a highly 
prevalent health problem in the developed and developing world. Asthma is charac-
terized by bronchial inﬂ  ammation, airway hyper-responsiveness induced by speciﬁ  c 
and nonspeciﬁ  c stimuli, and reversible bronchial obstruction with the appearance of 
respiratory symptoms such as dyspnea, chest tightness, wheezing, and cough. Air-
way inﬂ  ammation plays a central role in the pathogenesis of bronchial asthma and is 
associated with an increase in airway responsiveness to several trigger factors such as 
aeroallergens which induce bronchoconstriction in atopic asthma patients.Therapeutics and Clinical Risk Management 2007:3(4) 614
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The pathogenesis of bronchial asthma is not completely 
understood and it is well known that this clinical condition 
has a multifactorial etiology (D’Amato and Holgate 2002; 
Loddenkemper et al 2003; Masoli et al 2004; Rabe et al 2004). 
Although some asthmatic subjects exhibit a pathogenesis in 
which immunoglobulin E (IgE)-mediated mechanisms are 
not evident, asthma is almost always associated with some 
type of IgE-related reaction and therefore has an allergic 
basis (Holt et al 1999). Allergic bronchial asthma is a Th2 
mediated chronic inﬂ  ammatory disease of the airways, and 
IgE antibodies, Th2 derived cytokines, and eosinophils 
play a major role in the development of chronic airway 
inﬂ  ammation, which is observed even in subjects with very 
mild disease (Wenzel et al 1991; Busse et al 1995; Novak 
and Bieber 2003). In other words the development of 
inﬂ  ammation in asthma involves a complex array of several 
inﬂ  ammatory mediators that promote the recruitment and 
activation of various different immune cells (T-lymphocytes 
of the T-helper type 2 phenotype, eosinophils, macrophages/
monocytes, and mast cells) and regulate inﬂ  ammatory cell 
trafﬁ  cking into the lungs.
Activation of chemokine receptors triggers multiple 
cascades of intracellular signaling events that lead to 
recruitment and activation of immune effector cells. The 
inhibition of speciﬁ  c chemokines and receptors could prevent 
the excessive recruitment of inﬂ  ammatory cells into the 
airways. 
A number of selective chemokine receptor antagonists 
or anti-inﬂ  ammatory chemokines are currently at various 
stages of development, but there are no products yet ready 
for clinical use.
From IgE antibodies to therapy with 
monoclonal anti-IgE (omalizumab)
Elevated serum levels of speciﬁ  c IgE in response to common 
environmental aeroallergens are a key component in the 
pathogenesis of allergic asthma. IgE antibodies cause chronic 
airway inﬂ  ammation through effector cells such as mast cells 
and basophils activated via high-afﬁ  nity (FcεRI) or low-
afﬁ  nity (FcεRII) IgE receptors which bind these antibodies.
IgE is an immunoglobulin, consisting, like the other four 
antibody classes, of a variable antigen-binding fragment 
(Fab) region and a receptor-binding constant (Fc) region. 
The whole molecule consists of two heavy (H) ε chains and 
two light (L) chains of the k or λ type.
There is also high association between serum IgE levels 
and FcεRI receptors on precursor dendritic cells, and the 
expression of these receptors on antigen presenting cells 
such as dendritic cells is increased in asthmatic patients 
(Hollowaj 2001).
Since the discovery of IgE this antibody has been viewed 
as a target for novel immunological drug development in 
asthma, and a number of strategies to inhibit its proinﬂ  am-
matory action have been developed.
Current treatment for asthma suggested by the Global 
Initiative for Asthma (GINA) guidelines includes several 
drugs (relievers and controllers), in particular corticosteroids 
able to reduce recruitment and activation of inﬂ  ammatory 
cells, in particular eosinophils, in the airways (NHLBI -
GINA 2006). 
Previous GINA documents subdivided asthma into four 
categories by severity based on the level of symptoms, airﬂ  ow 
limitation, and lung function variability: Intermittent, Mild 
Persistent, Moderate Persistent, or Severe Persistent.
The GINA 2006 update recognizes, however, that asthma 
severity involves both the severity of the underlying disease 
and its responsiveness to treatment. In addition, severity is 
not an unvarying feature of an individual patient’s asthma, 
but may change over months or years. Therefore GINA, for 
this purpose, suggests that a periodic assessment of asthma 
control is more relevant and useful.
The burden of asthma is greatest in patients with in-
adequately controlled severe persistent asthma symptoms, 
limitations in normal daily activities, medical resource 
utilization, and both direct and indirect costs. 
The available treatments are effective for most of these 
asthma patients, but there are subjects affected by severe 
asthma who continue to experience debilitating disease, 
because their control is incomplete by inhaled or systemic 
corticosteroids associated with other drugs such as beta-2 
bronchodilators (short- and long-acting), leukotriene receptor 
antagonists (Bateman 2004; Partridge 2006).
These patients are at high risk of life-threatening exac-
erbation, hospitalization, and mortality (Tough 1998; Serra-
Batles et al 1998; Guite 1999) and are most affected in terms 
of quality of life (Turk 2005). 
The economic impact of asthma is considerable. 
Approximately US$13 billion were spent in the United 
States in 1998 (for indirect and direct cost) (Redd 2002) 
and €18 billion in Europe in 2003 (European Lung white 
book 2003).
Several studies have also indicated that asthma severity 
is associated not only with poor control, such as symptoms, 
recurrent hospitalization, lower quality of life (QoL), 
but also with higher social costs (Strunk and Bloomberg 
2006), and that the economic burden of asthma increases Therapeutics and Clinical Risk Management 2007:3(4) 615
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with asthma severity and is greatest in this patient group 
(Antonicelli et al 2004).
Omalizumab in the treatment 
of IgE-mediated (allergic) asthma
Omalizumab, an anti-IgE monoclonal antibody, can reduce 
free IgE levels avoiding the binding of IgE to FcεRI without 
the following development of allergic reaction (Boulet et al 
1997; Fahy et al 1997; Chang 2000; Fahy 2000; Holgate et al 
2001; Godard et al 2002; Kuehr et al 2002; Mankad et al 2003; 
D’Amato et al 2004, 2006). Omalizumab acts as a neutral-
izing antibody by binding IgE at the same site (Cε3 domain 
of Fc fragment) as the high afﬁ  nity receptor (FcεRI) binds 
IgE. Consequently, IgE effector functions (cross linking IgE 
and triggering degranulation and synthesis of new-generated 
chemical mediators of IgE-sensitized cells) and the following 
activation of mast cells and basophils are inhibited (Buhl et al 
2002a, b; Ayres et al 2004; Deniz and Gupta 2005; Holgate 
et al 2005) (Table 1). In other words in allergic subjects, and 
in the elderly (Milgrom et al 2001), omalizumab prevents 
the activation of cellular response and reduces occurrence of 
asthma symptoms (see Table 2).
Studies in patients with atopic asthma showed that anti-
IgE antibodies decrease serum IgE levels in a dose-dependent 
manner and allergen-induced bronchoconstriction during 
both the early and late-phase responses to inhaled allergen 
(Chang 2000; Fahy 2000).
Serum free IgE is dramatically reduced after omali-
zumab administration and the expression of high-afﬁ  nity 
receptors is signiﬁ  cantly reduced after 3 months’ treatment 
(MacGlashan et al 1997). Also, skin test reactivity is re-
duced by omalizumab (Togias et al 1998).
In patients who experience asthma associated with aller-
gic rhinitis there is an improvement also in nasal symptoms 
(Casale et al 1999; Adelroth et al 2000; Kopp et al 2002; 
Plewako et al 2002; Vignola et al 2004). Omalizumab 
administered together with speciﬁ  c immunotherapy can help 
to reduce risk of serious adverse events such as anaphylaxis 
and the need for epinephrine and corticosteroid use to treat 
adverse reactions (Casale 2006). However, omalizumab is 
useful also if used without contemporaneous administration 
of speciﬁ  c immunotherapy.
In several clinical controlled trials omalizumab reduced 
asthma-related symptoms, decreased corticosteroid use, 
and improved quality of life of asthmatic patients (Buhl 
et al 2002a, b; Ayres et al 2004; Deniz and Gupta 2005; 
Niebauer et al 2006). Recent studies show the beneﬁ  ts of 
anti-IgE as add-on therapy in patients with moderate and 
severe persistent asthma who are inadequately controlled by 
antiasthma pharmacological therapy. The anti-IgE approach 
to asthma treatment has several advantages, including con-
comitant treatment of other IgE-mediated diseases (allergic 
conjunctivitis and rhinitis, atopic dermatitis, and food allergy) 
and a favorable side-effect proﬁ  le regardless of the type of 
allergic sensitization (seasonal or perennial) (Casale et al 
1999; Adelroth et al 2000; Buhl et al 2002b; Plewako et al 
2002; Kopp et al 2002; Ayres et al 2004; Vignola et al 2004; 
Deniz and Gupta 2005). Omalizumab was shown not only to 
inhibit mast cell and basophil responses but also to have an 
inhibiting effect on inﬂ  ammatory cells, such as eosinophils, 
T lymphocytes, and B lymphocytes which are fundamental to 
the chronic inﬂ  ammatory response in allergic diseases such as 
asthma. This increased understanding places anti-IgE therapy 
ﬁ  rmly in the domain of an anti-inﬂ  ammatory treatment for 
chronic allergic disease, with effect on multiple cell types 
(Chang and Shiung 2006; D’Amato 2006).
Severe or refractory asthma remains a frustrating 
disease for both patients and the clinicians treating them 
(Busse et al 2000; Humbert et al 2005; Wenzel 2005; Moore 
et al 2007).
Severe asthma has been deﬁ  ned as persisting symptoms 
due to asthma despite high-dose inhaled steroids (1000 
µg beclometasone dipropionate or equivalent) plus long-
acting beta-2 agonist (LABA), with the requirement for either 
Table 1 Biological characteristics of omalizumab
•  Omalizumab expresses a high degree of isotype speciﬁ  city and can neutralize serum free IgE without affecting other antibody classes.
•  Omalizumab binds to serum free IgE and reduces IgE serum concentration, but does not bind to high- or low-afﬁ  nity IgE receptors on
 inﬂ  ammatory cells. However, it blocks IgE binding to these receptors and the IgE effector cells of inﬂ  ammation are “disarmed”.
•  Long-term treatment (3 months or more) with omalizumab induced down-regulation of the high-afﬁ  nity receptors on basophils and 
 dendritic  cells.
•  Omalizumab does not induce extensive immune complex formation, but only microcomplexes (thrimeric or exameric) which are not able
  to induce immune-complex pathology.
•  Omalizumab activity does not depend on the allergic-atopic sensitization to various types of aeroallergens (seasonal and/or perennial).
•  Omalizumab is active in case of IgE-mediated sensitization to one or more aeroallergens.Therapeutics and Clinical Risk Management 2007:3(4) 616
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maintenance systemic steroids or at least two rescue courses 
of steroids over 12 months and despite trials of add-ons such 
as leukotriene-receptor antagonist or theophylline.
The Global Initiative for Asthma (GINA) document for pa-
tients with uncontrolled asthma (step 5) recommends the use of 
high-dose inhaled corticosteroids plus a LABA, and, if required, 
one more additional controller such as omalizumab. 
Response to treatment can take several weeks to appear 
and it is suggested that patients should be treated for at least 
12 weeks before efﬁ  cacy is assessed (Bousquet et al 2005).
Experimental and controlled 
clinical studies
During the clinical trial on omalizumab 7 pivotal studies were 
performed on patients with moderate to severe IgE-mediated 
allergic asthma. One of these, the INNOVATE (INvestiga-
tioN of Omalizumab in seVere Asthma TrEatment) study, 
was speciﬁ  cally designed to evaluate the efﬁ  cacy and safety 
of add-on therapy with omalizumab in this difﬁ  cult-to-treat 
asthma population (Humbert et al 2005).
In the INNOVATE trial were enrolled patients aged 
12–75 years with severe persistent allergic asthma (GINA 
step 3 or 4 clinical features despite step 4 therapy). 108 centers 
in 14 countries participated in the study. Subjects enrolled 
had reduced lung function and not adequate symptom control 
despite therapy with a high dose of inhaled corticosteroids 
(ICS) (>1000 µg/day beclometasone dipropionate equivalent) 
and LABA stimulant bronchodilators, with a recent history 
of clinically signiﬁ  cant exacerbation. After a run-in phase, 
patients were randomized to receive double-blind therapy 
with omalizumab or placebo for 28 weeks.
The primary efﬁ  cacy variable was the rate of clinically 
signiﬁ  cant asthma exacerbations (deﬁ  ned as a worsening 
of asthma symptoms requiring treatment with systemic 
corticosteroids). Other efﬁ  cacy variables included the rate of 
severe exacerbations (peak expiratory ﬂ  ow (PEF) or forced 
expiratory volume in 1 second (FEV1) <60% of personal 
best, requiring treatment with systemic corticosteroids), 
total emergency visits for asthma, asthma-related quality of 
life (Juniper Adult Asthma Quality of Life Questionnaire; 
AQLQ), clinical symptom score, morning PEF, rescue medi-
cation use, and global evaluation of treatment effectiveness 
by patients and investigators. Safety was evaluated by observ-
ing adverse events and by monitoring laboratory parameters 
and vital signs. A total of 419 patients were included in the 
efﬁ  cacy analyses (omalizumab, n = 209; placebo, n = 210). 
All patients were receiving ICS and LABA and two-thirds 
were receiving additional controller medications (includ-
ing 22% oral corticosteroids). Patients had experienced an 
average of 2.1 exacerbations per year requiring systemic 
corticosteroids and 67% were considered at high risk of 
asthma-related death (based on previous history of emer-
gency department or hospital visits or intubations).
After adjusting for an observed imbalance in asthma exac-
erbation history prior to randomization, the rate of clinically 
signiﬁ  cant asthma exacerbations was signiﬁ  cantly reduced 
by 26.2% with omalizumab versus placebo (0.68 and 0.91, 
respectively; p = 0.042).
Treatment with omalizumab signiﬁ  cantly reduced the rate 
of severe asthma exacerbations in comparison with placebo 
(0.24 vs 0.48, p = 0.002) and the rate of total emergency visits 
for asthma (0.24 vs 0.43, p = 0.038). Signiﬁ  cantly greater 
improvements were obtained with omalizumab compared 
with placebo in AQLQ scores, with a signiﬁ  cantly greater 
proportion of patients receiving omalizumab achieving 
a clinically meaningful (>0.5-point) improvement from 
baseline compared with placebo treated patients (61% and 
48%, respectively; p = 0.008).
Table 2 Omalizumab in clinical studies in allergic asthma patients 
Omalizumab has been shown to:
  •  Decrease IgE-induced bronchoconstriction during both the early- and late-phase responses to inhaled allergen during the bronchial 
 provocation  tests.
  •  Reduce skin prick test response to allergenic extracts.
  •  Reduce asthma exacerbations regardless of the type of seasonal or perennial allergic sensitization.
  •  Have a corticosteroid sparing effect.
  •  Reduce the use of bronchodilators.
  •  Improve also the nasal symptoms in subjects with allergic rhinitis associated with asthma.
  •  Improve quality of life in patients with asthma, and also in those with severe persistent allergic asthma that is inadequately controlled by
  currently available asthma medication.
 • Have a reassuring safety proﬁ  le similar to that of placebo. In malignant neoplasms observed in patients treated with omalizumab, blinded
  and unblended expert oncologist review showed that the neoplasms were most likely pre-existent and there was no evidence that any of
  neoplasms were linked causally to omalizumab treatment.Therapeutics and Clinical Risk Management 2007:3(4) 617
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The overall changes from baseline in mean morning 
PEF (p = 0.042) and total asthma symptom score 
(p = 0.039) during the treatment period were also 
significantly greater with omalizumab, which was 
considered more effective than placebo (p < 0.001) by 
both investigators and patients. 
The pooled data from all clinical studies in patients with 
severe persistent asthma show that omalizumab is highly 
efficacious as add-on treatment to concomitant asthma ther-
apy, as shown by the consistent reduction in asthma exacer-
bation rates compared with control-treated patients. Overall, 
exacerbations were significantly reduced (p < 0.0001) by 
38.3% (annualized rate: 0.910 vs 1.474) with omalizumab 
compared with the control group (Table 3).
Omalizumab significantly reduced the rate of emergency 
visits for asthma care by 47% compared with control therapy 
(p < 0.0001). Hospital admissions were reduced by 52%, 
emergency room visits by 61%, and unscheduled doctor 
visits by 47% (Bousquet 2005). 
The clinical study showed also that side-effects following 
treatment with omalizumab were mild to moderate and did 
not differ significantly from placebo with the exception of 
injection site reactions, and no anti-omalizumab antibody 
response has been observed (Walker 2006). 
A recent exploratory study on allergic subjects living 
in poor urban areas of Brazil, at high risk of helminthes 
infections, showed that omalizumab appeared to be effec-
tive and safe, but may be associated with a possible slightly 
increased risk of infections (not statistically significant) 
(Cruz 2007).
Further studies will need to focus on the utility of long-
term treatment with anti-I gE to reduce the risk of life-threating 
reactions in subjects with food allergy, latex allergy, or stinging 
insect hypersensitivity.
Preparation for use
Omalizumab is administered by subcutaneous injection. The 
appropriate dose and dosing frequency of omalizuamb is 
determined by baseline IgE (IU/mL) measured before start 
of treatment, and body weight (kg). Based on these measure-
ments, 75–375 mg of omalizumab in 1–3 injections may be 
needed for each administration. 
Omalizumab is supplied as a lyophilized, sterile powder 
in single-use, 5-mL vials designed to deliver either 150 or 
75 mg on reconstitution with sterile water for injection. The 
powder requires 15–20 minutes or more to dissolve. The 
solution is viscous and must be carefully drawn up into the 
syringe before it is administered. Usually the injection needs 
5–10 seconds for administration. Once prepared, omalizumab 
must be injected within 4 hours if at room temperature or 8 
hours if refrigerated. I t is important to schedule appointment 
for injection, avoiding preparing injection until the patient 
arrives. This results in visits that take 1 hour or more, 
since 30 minutes of observation after the injection are 
recommended.
Total serum I gE levels are generally increased during 
treatment, since there are circulating I gE-antiI gE complexes 
(Hamilton et al 2005).
Conclusions
Studies of patients with allergic asthma show that anti-IgE 
treatment with omalizumab has a reassuring safety proﬁ  le. 
The drug was approved for commercial use in allergic asthma 
by the Federal Drug Administration in June 2003 and by the 
European Agency for Evaluation of Medicinal Products in 
July 2005.
Analysis of data from controlled clinical trials carried 
with patients affected by severe allergic asthma showed that 
omalizumab is well-tolerated and safe both in short-term and 
Table 3 Reduction in asthma exacerbation rates across studies
    Rate per year      Exac. rate
       P-Value  for    treatment 
   Omalizumab  Control  rate  ratio  difference
INNOVATE study  1.37  1.86  0.042  0.49
ETOPA study1 0.98  2.47 <0.001  1.49
SOLAR study2 0.49  0.79 0.027  0.29
Busse study3,4 0.59  0.99 <0.001  0.40
Solèr study5,6 0.51  1.21  <0.001  0.70
Holgate study7 1.18  1.60  0.165  0.42
ALTO safety study  1.02  1.20  0.077  0.18
Pooled 0.91  1.47  <0.001  0.56
1) Ayres et al 2004; 2) Vignola et al 2004; 3) Busse et al 2001; 4) Lanier et al 2003; 5) Solèr et al 2001; 6) Buhl et al 2002; 7) Holgate et al 2004.Therapeutics and Clinical Risk Management 2007:3(4) 618
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long-term studies. I t is well tolerated, and its overall adverse 
event profile is similar to that of placebo.
Several clinical studies have shown no evidence that 
omalizumab enhanced the risk of anaphylactic reactions, 
infections or parasitic infestations, or bleeding-related or 
any immune complex diseases or similar syndromes. As 
for malignant neoplasms observed in patients treated with 
omalizumab during a pivotal trial, blinded and unblended 
expert oncologists review showed that the neoplasms were 
most likely pre-existent and there was no evidence that any of 
neoplasms were linked causally to omalizumab treatment.
Because omalizumab is administered infrequently, with 
twice-monthly or monthly dosing, anti-I gE therapy may be 
useful in patients who have difficulty in complying with 
daily treatment.
Since omalizumab treatment induces a reduction in Fc￿RI  
and I gE+ cells in the airways of asthma patients and because 
a relationship between Fc￿RI  expression and fatal asthma has 
been hypothesized (Fregonese et al 2004), the possible effect 
of omalizumab in reducing the risk of mortality induced by 
severe asthma should be considered.
A recent study demonstrated that omalizumab add-
on in patients with severe allergic asthma results in a 
cost-per-quality-adjusted life year ratio that compares 
favorably with other uses of scarce healthcare resources that 
are recommended by national reimbursement bodies and 
could be considered cost-effective. I n the current climate of 
scarce healthcare resources, it is important to demonstrate 
both economic value as well as therapeutic value of a treat-
ment (Brown 2007). Omalizumab offers both therapeutic 
and economic value and represents a major advance for the 
treatment of patients with inadequately controlled severe 
persistent allergic asthma.
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